Dr. MacVittie, a professor of radiation oncology and pathology at the University of Maryland School of Medicine and a member of the Molecular and Structural Biology Program at the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, is recognized internationally as an expert on the effects of radiation on the hematopoietic and gastrointestinal systems in large animal models and their treatment, in vivo, with supportive care and selected organ-specific drugs.
He earned M.S. and Ph.D. degrees in radiation biology at the State University of New York (SUNY) at Buffalo and has more than 30 years of experience as a radiobiologist in the field of experimental hematology. He has published 141 peer-reviewed manuscripts and 43 chapters in books or proceedings.
Dr. MacVittie has served as an advisor to the WHO Collaborating Centers in Radiation Emergency Medical Preparedness and Assistance and the International Council on Radiation Protection and as a member of NATO Radiation Research Study Groups. He is a member of the CDC Strategic National Stockpile Radiation Working Group, the International Association of Radiopathology, the American Society of Hematology, the International Society of Experimental Hematology, Radiation Research and the International Society of Cellular Therapy. Dr. MacVittie is a member of the editorial board of the journal Stem Cells and serves as an ad hoc reviewer for numerous journals and National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIAID) and Department of Defense grants and contracts. He is also a consultant for the International Atomic Energy Agency (IAEA) and Canadian Defense Research Establishment. Dr. MacVittie was recently invited by the Secretary, U.S. Department of Health and Human Services, to serve on the first National Biodefense Science Board Federal Advisory Committee.
His early work clearly demonstrated the efficacy of supportive care and hematopoietic growth factors on increasing survival in lethally irradiated large animal models. The MacVittie group's database demonstrating the effect of cytokines on enhancing survival and recovery of hematopoiesis serves as the focal point for current efforts to design the first pivotal trial under the FDA's "animal rule" to determine the treatment efficacy of candidate drugs/biologics for final FDA approval.
Dr. MacVittie is the principal investigator of the sole research contract ($47million/five years) awarded by NIAID to assess the efficacy and mechanism of action for Medical Countermeasures Against Radiological Threats (MCART). The MCART consortium has 15 research and administrative components in the United States, Canada and England.
Radiation injury, hematopoiesis, gastrointestinal stem cells
Dr. MacVittie has had more than 140 peer-reviewed journal articles published. His most recent ones include:
MacVittie, T.J., Farese, A. M., Smith, W.G., Baum, C. M., Burton, E., McKearn, J. P. (2000) Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood 95:837-845.
Farese, A.M., Smith, W.G., Giri, J.G., Siegel, N., McKearn, J.P, MacVittie, T.J. (2001) Promegapoietin, an engineered chimeric IL-3 and mpl-L agonist stimulates hematopoietic recovery in an abbreviated schedule following radiation-induced myelosuppression in nonhuman primates. Stem Cells, 19:329-338.
King, A., Horowitz, D., Dillon, S., Levin, R., Farese, A., MacVittie, T., Pelus, L. (2001) Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GROb. Blood, 97:1534-1542.
Farese, A..M., Casey, D.B., Smith, W.G., Vigneulle, R.M., McKearn, J.P., MacVittie, T.J. (2001) Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: Effect of schedule, dose and route of administration. Stem Cells, 19:522-533.
Farese, A..M., Casey, D.B., Vigneulle, R.M., Siegel, N.R., Finn, R.F., Klover, J.A., Smith, W.G., McKearn, J.P., MacVittie, T.J. (2001) A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. Stem Cells, 19:514-521.
McAfee J.G., MacVittie, T.J. (2001) The impact of recent advances in immunology and cancer therapy on nuclear medicine. Semin Nucl Med 31(4):342-9.
MacVittie, T. J., Farese, A. M., (2002) Cytokine-based treatment of radiation-injury: Is there a potential benefit following low level radiation exposure. J. of Military Medicine, 167, Suppl. 1:068-070.
Vigneulle, R.M., Srinivasan, S., Fasano, A., MacVittie, T.J. (2002) Structural and functional alterations of the gastro-intestinal tract following radiation-induced injury in the rhesus monkey. Digestive Diseases and Sciences 47:1480-1491.
Farese, A.M., MacVittie, T.J., Roskos. L., Stead, R. B. (2003) Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: Effect of variation in treatment schedule with PEG-rHuMGDF. Stem Cells 21:79-89.
Smith, D.E, Hanna, R., Friend, D., Moore, H., Chen, H, Farese, A..M, MacVittie, T.J., Virca, G.D., Sims, J.E., (2003) The soluble form of IL-1 receptor accessory protein is abundant in normal serum and enhances the ability of soluble type II IL-1 receptor to inhibit IL- action. Immunity 18:87-96.
Coleman, C.N., Blakely, W.F., Fike, J.R., MacVittie, T.J., Metting, N.F., Mitchell, J.B., Moulder, J.E., Preston, R.J., Seed, T.M., Stone, H.B., Tofilon, P.J., Wong, R.S.L. (2003) Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: Report of a workshop at Bethesda, MD, Dec 17-18, 2001., Radiation Research 159:812-834.
Farese, A.M., Yang, B-B., Roskos, L., Stead, R.B., MacVittie, T.J. (2003) Pegfilgrastim, a sustained-duration form of filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques. Bone Marrow Transplantation 32:399-404
Poliakova, L., Pirone, A.T., Farese, A.M., MacVittie, T.J., Farney, A. (2004) Presence of nonhematopoietic side population cells in the adult human and non-human primate pancreas. Transplantation Proceedings 36:399-404.
Koopman, G., Niphuis, J., Haaksma, A.G., Farese, A.M., Casey, D.B., Kahn, L.E., Mann, D., MacVittie, T.J., Woulfe, S.L., Heeney, J.L. (2004) Increase in plasmacytoid and myeloid dendritic cells by progenipoietin-1, a chimeric Flt-3 and G-CSF receptor agonist, in SIV-infected rhesus macaques. Hum Immunol. 65(4):303-16.
Waselenko, J.K., MacVittie, T.J., Blakely, W.F., Pesik, N., Wiley, A. L., Dickerson, W.E., Tsu, H., Conifer, D.L., Coleman, C. N., Seed, T., Lowry, P., Armitage, J.O., Dainiak, N. (2004) Medical management of acute radiation syndrome: recommendations of the strategic national stockpile radiation working group. Annals of Internal Medicine. Ann Intern Med 140(12):1037-51.
Stone, H.B., Moulder, J.E., Coleman, C.N., Ang, K.K., Anscher, M.S., Barcellos-Hoff, M.H., Dynan, W.S., Fike, J.R., Grdina, D.J., Greenberger, J.S., Hauer-Jensen, M., Hill, R.P., Kolesnick, R.N., MacVittie, T.J., Marks, C., McBride, W.H., Metting, N.F., Pellman, T., Purucker, M., Robbins, M.E., Schiestl, R.H., Seed, T.M., Tomaszewski, J.E., Travis, E. L., Wallner, P.E., Wopert, M., Zaharevitz, D., (2004) Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries report of an NCI workshop, December 3-4, 2003. Radiation Research 162:711-728.
Yusibov, V., Mett, V., Mett, V., Davidson, C., Musiychuk, K., Gilliam, S., Farese, A., MacVittie, T., Mann, D.(2005) Peptide-based candidate vaccine against respiratory syncytical virus. Vaccine 23:2261-65.
Koopman G, Mortier D, Niphuis H, Farese AM, Kahn LE, Mann D, Wagner R, Macvittie TJ, Woulfe SL, Heeney JL. (2005) Systemic mobilization of antigen presenting cells, with a chimeric Flt-3 and G-CSF receptor agonist, during immunization of Macaca mulatta with HIV-1 antigens is insufficient to modulate immune responses or vaccine efficacy. Vaccine. 2005 May 13
MacVittie TJ, Farese AM, Jackson W 3rd. (2005) Defining the Full Therapeutic Potential of Recombinant Growth Factors in the Post Radiation-Accident Environment: The effect of supportive care plus administration of G-CSF. Health Phys. 89(5):546-55.
Sebastian B., Ryser,M.F., Choi, U., Whiting-Theobald, N., Kuhlisch, E., Linton, G., Kang, E., Lehmann, R., Roesler, J., Rosen-Wolff, A., Rudikoff, A.G., Farese, A.M., MacVittie, T.J., Horwitz, M.E., Malech, H.L. (2005) Polyclonal long-term MFGS-gp91phox marking in rhesus macaques after non-myeloablative transplantation with transduced autologous peripheral blood progenitor cells. (2005) Molecular Therapy, 14(2):202-11.
Ossetrova, N.I., Farese, A.M., MacVittie, T.J., Manglapus, G.L., Blakely, W.F. (2007) The use of discriminant analysis for evaluation of early-response multiple biomarkers of radiation exposure using non-human primate 6-Gy whole-body radiation model. Radiation Measurements. 42(6-7) 1158-1163.
Lenz, P., Hankey, K.G., MacVittie, T., Farese, A., Nakajima, K., Hasumi, K., Mann, D. L. (2008) Products of anti-DC3/antio-CD28 activated lymphocytes induce differentiaion and maturation of dendritic cells and has adjuvant-like activity in vitro and in vivo. Clinical Immunology 129 (2) 179-380.
Recent Publications as Manuscript or Chapters in Books/Proceedings
MacVittie, T.J., Monroy, R.L. (1990) Potential improvement in the survival of seriously irradiated persons. IN: The Medical Basis for Radiation Accident Preparedness: II. Clinical Experience and Follow-up since 1979. (eds) Ricks, R.C. and Fry, S.A. Elsevier Scientific Publishing Co.
MacVittie, T.J., Monroy, R.L. (1990) Rescue of lethally irradiated animals: Therapeutic use of rhG-CSF and rhGM-CSF in preclinical models of radiation-induced marrow aplasia. IN: Treatment of Radiation Injuries, (eds) Browne, D., Weiss, J., MacVittie, T.J., Pillai, M.V., Plenum Press, New York.
Davis, T.A., Monroy, R. L., Donahue, R. E., MacVittie, T.J (1990) GM-CSF: a regulatory molecule for NK activity in the bone marrow. IN: Molecular and Cellular Biology of Cytokines. (Dinarello, C.A., Kluger, M., Powanda, M., and Oppenheim, Eds).
Monroy, R.L., Davis, T.A., MacVittie, T.J. (1990) Short analytical review: Granulocyte-macrophage colony-stimulating factor: More than a hemopoietin. Clin. Immunol. Immunopathol. 54:333.
MacVittie, T.J., Monroy, R.L., Farese, A.M., Patchen, M.L., Seiler, F.R., Williams, D.E. (1991) Cytokine therapy in canine and primate models of radiation-induced marrow aplasia. Rizzoli, V., Schulz, G., Seiler, F.R. (eds) Behring Inst. Mitt. 90:1-13.
Patchen, M.L., MacVittie, T.J., Souza, L.M. (1992) Synergy between G-CSF and WR-2721: Effects on enhancing hemopoietic reconstitution and increasing survival following exposure to ionizing radiation. IN: Combination Therapies for the Treatment of Cancer and Infectious Diseases. A.L. Goldstein, ed. Plenum Publishing, New York, NY. pp 215-222.
Patchen, M.L., MacVittie, T.J., Solberg, B.D., Fischer, R., Souza, L.M. (1993) Cytokine treatment of radiation-induced hemopoietic suppression: Results of interleukin-6 and granulocyte colony-stimulating factor in a murine radiation model. IN: Host Defense Dysfunction in Trauma, Shock, and Sepsis. E. Faist, Meakins, and Schildberg, eds. Springer Verlag, Berlin. pp 693-698.
Patchen, M.L., Fischer, R., MacVittie, T.J., Seiler, F., Williams, D.E. (1994) Single and combination cytokine therapies for treatment of radiation-induced hematopoietic injury: Effects of c-kit ligand and interleukin-3. IN: Molecular Biology of Haematopoiesis. Abraham, N.G., Shadduck R.K., Levine, A.S., Takaku, F. eds, Intercept Ltd. Andover, Hamshipre, UK. pp. 83-94.
Patchen, M.L., MacVittie, T.J. (1994) Granulocyte colony stimulating factor and amifostine synergize to enhance hemopoietic reconstitution and increase survival in irradiated animals. In: Seminars in Oncology. (In Press)
MacVittie, T.J. and Farese, A.M. (1995) Experimental approaches to treatment of radiation-induced hemopoietic injury. Lord, B., and Hendry, J., eds. IN: Radiation Toxicology: Bone Marrow and Leukemia. Taylor and Francis, London. pp 141-193.
Farese, A. M. and MacVittie, T.J. (1997), Efficacy of MPL ligand and other thrombopoietic cytokines in animal models. Kuter, D., Hunt, P., Sheridan, W. P., Zucker-Franklin, D., eds. IN: Thrombopoiesis and the thrombopoietins; molecular, cellular, and clinical biology. Humana Press. Totowa, NJ. pp 321-347.
Farese, A. M., MacVittie, T.J., Schiffer, C. A. (1996), Potential impact of MPL ligand and other thrombopoietic cytokines on transfusion medicine practice. Blajchman, M.A. ed. IN: Transfusion Medicine Reviews, W.B. Saunders Company, Philadelphia, PA. 11:243-255.
MacVittie, T.J. (1997) Commentary: Therapy of radiation injury. Stem Cells 15 (suppl 2): 263-268.
MacVittie, T.J. and Farese, A.M. (2001) Cytokine-based treatment for acute radiation-induced myelosuppression: Preclinical and clinical perspective. Ricks, R.C., Berger, M.E., O’Hara, Jr., F. M ed. IN: The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victims, The Parthenon Publishing Group, Pearl River, NY. pp 53-72.
Coleman, C.N., Blakely, W.F., Fike, J.R., MacVittie, T.J., Metting, N.F., Mitchell, J.B., Moulder, J.E., Preston, R.J., Ricks, R.C., Seed, T.M., Stone, H.B., Tofilon, P.J., Wong, R.S.L. (2003) Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: Report of a workshop at Bethesda, Maryland, December 17-18, 2001. Radiation Research 159: 812-834
MacVittie, T.J. and Farese, A.M. (2003) New directions in growth factor therapy. Dainiak, N., Waselenko, J.K., Armitage, J., MacVittie, T.J., and Farese, A. M. ed. IN: The hematologist and radiation casualties. The American Society for Hematology Education Program Book, Washington, D.C. pp 488-496
Farese, A. M., MacVittie, T.J. (2003) Hematopoietic growth factors: preclinical studies of myeloid and immune reconstitution. Morstyn, G., Foote, M.A., Leishchke, G., eds. IN: Hematology growth factors for oncology. Humana Press. Totowa, NJ. pp 185-207
Stone, H.B., Moulder, J.E., Coleman, C.N., Aig, K.K., Anscher, M.S., Barcellos-Hoff, M.H., Dyan, W.S., Fike, J.R., Grdina, D.J., Greenberger, J.S., Hauer-Jensen, M., Hill, R.P., Kilesnick, R.N., MacVittie, T. J., Marks, C., McBride, W.H., Metting, N., Pellmar, T., Purucker, M., Robbins, M.E., Schiestl, R. H., Seed, T.M., Tomaszewski, J.E., Travis, E.L., Wallner, P.E., Wolpert, M., Zaharevitz, D. (2004) Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries report of an NCI workshop, Dec 3-4, 2003. Radiation Research 162:711-728